W. Keane

H. Oda, W. Keane, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The effect of famotidine on renal function in patients with renal insufficiency.

W. Keane, G. Matzke, C. Halstenson, 1987, British journal of clinical pharmacology.

Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin.

B. Kasiske, W. Keane, Youngki Kim, 1995, Kidney international.

Lovastatin retards the progression of established glomerular disease in obese Zucker rats.

B. Kasiske, W. Keane, P. Schmitz, 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Oxidative modification of low-density lipoproteins by mesangial cells.

B. Kasiske, W. Keane, Youngki Kim, 1993, Journal of the American Society of Nephrology : JASN.

Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats.

B. Kasiske, Z. Massy, W. Keane, 1998, American Journal of Kidney Diseases.

Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells.

B. Kasiske, Z. Massy, W. Keane, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.

B. Kasiske, W. Keane, Y. Kim, 1994, Kidney international. Supplement.

Lipid abnormalities in patients with chronic kidney disease.

J. Tomassini, W. Keane, D. Neff, 2011, Contributions to nephrology.

The role of lipid abnormalities in the pathogenesis of chronic, progressive renal disease.

B. Kasiske, W. Keane, P. Schmitz, 1991, Advances in nephrology from the Necker Hospital.

Lipids and progressive renal failure.

W. Keane, 1996, Wiener klinische Wochenschrift.

CHAPTER 67 – Management of Hyperlipidemia in Chronic Dialysis Patients

Z. Massy, W. Keane, 2008 .

Acute glomerulonephritis. A clinical overview.

W. Keane, R. Vernier, K. Whitley, 1984, The Medical clinics of North America.

Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update.

B. Piraino, T. Golper, F. Schaefer, 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update

B. Piraino, T. Golper, W. Keane, 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Recommendations for reducing the high morbidity and mortality of United States maintenance dialysis patients. The National Kidney Foundation.

W. Keane, R. Hakim, P. Held, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The role of altered lipid metabolism in the progression of renal disease: experimental evidence.

B. Kasiske, W. Keane, Y. Kim, 1991, American Journal of Kidney Diseases.

Effects of genetic obesity on renal structure and function in the Zucker rat.

B. Kasiske, W. Keane, M. Cleary, 1985, The Journal of laboratory and clinical medicine.

Intravascular and extracellular volumes in the diabetic rat.

W. Keane, K. Ilstrup, L. Michels, 1981, Life sciences.

Determinants of glomerular filtration and plasma flow in experimental diabetic rats.

W. Keane, L. Michels, M. Davidman, 1981, The Journal of laboratory and clinical medicine.

The assessment of risk factors in 462 patients with acute renal failure.

W. Keane, M. Finkelstein, M. Finkelstein, 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd.

B. Brenner, W. Keane, A. Mazzu, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update. The Ad Hoc Advisory Committee on Peritonitis Management.

T. Golper, W. Keane, R. Gokal, 1989, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Treatment Recommendations 1993 Update

T. Golper, W. Keane, H. Verbrugh, 1993 .

Hypertension, hyperlipidemia, and renal damage.

B. Kasiske, W. Keane, Y. Kim, 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Lipid-lnduced Glomerular Injury

W. Keane, C. Guijarro, 1994 .

Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis.

T. Golper, W. Keane, H. Verbrugh, 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Infectious Complications in Maintenance Dialysis Patients

W. Keane, L. Raij, 1979 .

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

W. Keane, S. Shahinfar, C. Alexander, 2004, Kidney international. Supplement.

Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.

B. Brenner, W. Keane, S. Shahinfar, 2005, Kidney international. Supplement.

Editors JORDAN J. COHEN

W. Keane, 1994 .

Role of lipid peroxidation in the inhibition of mononuclear cell proliferation by normal lipoproteins.

B. Kasiske, W. Keane, 1991, Journal of lipid research.

Hyperlipidemia in the nephrotic syndrome.

B. Kasiske, W. Keane, 1990, The New England journal of medicine.

Glucose-induced Increases in Renal Hemodynamic Function: Possible Modulation by Renal Prostaglandins

B. Kasiske, W. Keane, M. O'Donnell, 1985, Diabetes.

Lipophilic statins induce apoptosis of human vascular smooth muscle cells.

B. Kasiske, Z. Massy, W. Keane, 1999, Kidney international. Supplement.

Protective Effect of HMG-CoA Reductase Inhibitor on Experimental Renal Ischemia-Reperfusion Injury

B. Kasiske, H. Rabb, F. Daniels, 2002, American Journal of Nephrology.

Treatment of hyperlipidemia in chronic progressive renal disease.

B. Kasiske, W. Keane, Y. Kim, 1993, Current opinion in nephrology and hypertension.

Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.

W. Keane, C. Guijarro, 1996, Mineral and electrolyte metabolism.

Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin.

B. Kasiske, Z. Massy, W. Keane, 2000, Biochemical and biophysical research communications.

Rabeprazole: Pharmacokinetics and Tolerability in Patients with Stable, End‐Stage Renal Failure

W. Keane, S. Swan, T. Humphries, 1999, Journal of clinical pharmacology.

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.

B. Kasiske, J. Velosa, W. Keane, 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Determinants of glomerular mesangial localization of immune complexes. Role of endothelial fenestrae.

W. Keane, L. Raij, 1981, Laboratory investigation; a journal of technical methods and pathology.

Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats.

B. Kasiske, W. Keane, P. Schmitz, 1992, Hypertension.

Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?

B. Kasiske, W. Keane, J. S. St. Peter, 1992, Kidney international. Supplement.

The central role of nuclear factor-κB in mesangial cell activation

B. Kasiske, Z. Massy, W. Keane, 1999 .

Lovastatin inhibits proliferation of rat mesangial cells.

B. Kasiske, W. Keane, Y. Kim, 1993, Journal of Clinical Investigation.

NephrologyDialysis Transplantation Lovastatin inhibits lipopolysaccharide-induced NF-#cB activation in human mesangial cells

B. Kasiske, Z. Massy, W. Keane, 2005 .

Regulation of mesangial cell proliferation by the mevalonate pathway.

B. Kasiske, Z. Massy, W. Keane, 1997, Contributions to nephrology.

Antimicrobial Treatment of Peritonitis Associated with Continuous Ambulatory Peritoneal Dialysis

W. Keane, G. Matzke, S. Millikin, 1991, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

T. Golper, W. Keane, R. Fine, 1987 .

Pharmacokinetics of Zileuton and Its Metabolites in Patients with Renal Impairment

R. Hansen, W. Keane, C. Halstenson, 1997, Journal of clinical pharmacology.

Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats.

B. Kasiske, W. Keane, M. Cleary, 1989, Kidney international.

The role of lipids in progressive glomerular disease.

B. Kasiske, W. Keane, M. O'Donnell, 1987, Advances in experimental medicine and biology.

Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril.

B. Kasiske, W. Keane, P. Schmitz, 1992, The American journal of physiology.

Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines.

B. Kasiske, Z. Massy, W. Keane, 1997, Contributions to nephrology.

Radiation-induced renal disease. A clinicopathologic study.

W. Keane, F. Shapiro, J. Crosson, 1976, The American journal of medicine.

The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats.

B. Kasiske, W. Keane, S. Swan, 1995, Journal of the American Society of Nephrology : JASN.

Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency.

W. Keane, C. Halstenson, J. Opsahl, 1988, Archives of internal medicine.

Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1.

W. Keane, P. Schlievert, P. Peterson, 1986, The American journal of pathology.

Mesangial function in ureteral obstruction in the rat. Blockade of the efferent limb.

A. Michael, W. Keane, H. Osswald, 1979, The Journal of clinical investigation.

Lipids and progressive renal disease: the cardio-renal link.

W. Keane, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Lipids in progression of renal disease.

H. Oda, W. Keane, 1997, Kidney international. Supplement.

Lipids and the progression of renal disease.

B. Kasiske, W. Keane, P. Schmitz, 1990, Journal of the American Society of Nephrology : JASN.

Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats.

B. Kasiske, W. Keane, H. Lee, 1991, Kidney international.

Host Defenses and Infectious Complications in Maintenance Hemodialysis Patients

A. Collins, W. Keane, A. Rinehart, 1996 .

Adriamycin-induced chronic proteinuria: a structural and functional study.

B. Kasiske, W. Keane, L. Raij, 1985, The Journal of laboratory and clinical medicine.

Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway.

W. Keane, H. Verbrugh, P. Peterson, 1985, Immunology.

The central role of nuclear factor-kappa B in mesangial cell activation.

B. Kasiske, Z. Massy, W. Keane, 1999, Kidney international. Supplement.

Isoprenoids, Ras and proliferative glomerular disease.

B. Kasiske, Z. Massy, W. Keane, 1997, Contributions to nephrology.

The obese Zucker rat model of glomerular injury in type II diabetes.

B. Kasiske, W. Keane, M. O'Donnell, 1987, The Journal of diabetic complications.

Alterations in glomerular proteoglycan metabolism in experimental non-insulin dependent diabetes mellitus.

B. Kasiske, W. Keane, P. Fioretto, 1993, Journal of the American Society of Nephrology : JASN.

Polymorphonuclear leukocyte, T-lymphocyte, and natural killer cell activities in elderly nursing home residents

W. Keane, P. Peterson, G. Gekker, 1986, European Journal of Clinical Microbiology.

Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids

W. Keane, H. Verbrugh, P. Peterson, 1984, Journal of clinical microbiology.

Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells.

B. Kasiske, H. Oda, W. Keane, 1999, Kidney international. Supplement.

Risk factors for glomerular injury in rats with genetic hypertension.

B. Kasiske, W. Keane, M. O'Donnell, 1989, American journal of hypertension.

Renal disease in cryoglobulinemia type II: response to therapy. A case report and review of the literature.

W. Keane, M. Germain, R. Anderson, 1982, American journal of nephrology.

Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

B. Brenner, H. Parving, G. Remuzzi, 2004, Circulation.

Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure

W. Keane, C. Guijarro, 1993, Current opinion in nephrology and hypertension.

Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis.

W. Keane, L. R. Freedman, 1967, The Yale journal of biology and medicine.

Successful renal transplantation in progressive systemic sclerosis.

W. Keane, L. Raij, B. Danielson, 1976, Annals of internal medicine.

Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin.

A. Michael, W. Keane, L. Raij, 1977, Kidney international.

Host Defense Mechanisms of the Peritoneal Cavity and Continuous Ambulatory Peritoneal Dialysis

W. Keane, P. Peterson, 1984 .

Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis.

W. Keane, H. Verbrugh, P. Peterson, 1984, Kidney international.

The Influence of Hemodynamic Factors upon Mesangial Kinetics of Macromolecules

W. Keane, L. Raij, 1983 .

Human peritoneal macrophage phagocytic, killing, and chemiluminescent responses to opsonized Listeria monocytogenes

W. Keane, A. MacGowan, P. Peterson, 1983, Infection and immunity.

Peritonitis and Other Complications

W. Keane, C. Halstenson, 1998 .

Effects of Nephron Loss on Glomerular Hemodynamics and Morphology in Diabetic Rats

B. Kasiske, F. Daniels, W. Keane, 1986, Diabetes.

Glomerular hemodynamic and structural correlations in long-term experimental diabetic rats.

W. Keane, L. Michels, M. O'Donnell, 1984, The Journal of laboratory and clinical medicine.

Lipids and progressive renal injury.

B. Kasiske, W. Keane, P. Schmitz, 1989, Seminars in nephrology.

Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition.

W. Keane, L. Raij, 1980, Laboratory investigation; a journal of technical methods and pathology.

The effects of chronic mesangial immune injury on glomerular function.

W. Keane, L. Michels, M. Davidman, 1980, The Journal of laboratory and clinical medicine.

Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition.

W. Keane, L. Raij, R. Sibley, 1981, The Journal of laboratory and clinical medicine.

Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes.

B. Kasiske, W. Keane, G. Gekker, 1998, Kidney international.

The mevalonate pathway: importance in mesangial cell biology and glomerular disease.

B. Kasiske, W. Keane, Y. Kim, 1993, Mineral and electrolyte metabolism.

Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis.

W. Keane, G. Matzke, P. Peterson, 1987, Reviews of infectious diseases.

Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis.

W. Keane, H. Verbrugh, P. Peterson, 1983, The Journal of infectious diseases.

Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing

W. Keane, G. Matzke, C. Halstenson, 1989, Antimicrobial Agents and Chemotherapy.

Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations: 1989 Update

T. Golper, W. Keane, G. Matzke, 1989 .

Experimental pyelonephritis in the mouse

W. Keane, 1968 .

Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages

W. Keane, P. Peterson, G. Gekker, 1984, Infection and immunity.

Host Defense Mechanisms in Chronic Ambulatory Peritoneal Dialysis—Associated Peritonitis

W. Keane, M. Harrison, 1989 .

Pharmacokinetics of MAT9001, an Omega‐3 Fatty Acid Medication, Compared with Eicosapentaenoic Acid Ethyl Esters in Hypertriglyceridemic Subjects

W. Keane, K. Maki, G. Bobotas, 2016 .

Glomerular, mesangial and tubular function in mercury chloride (HgCl2) acute renal failure (ARF)

W. Keane, L. Raij, S. Azar, 1977 .

Degenerative and age-related changes in the x-irradiated kidney of the rat.

W. Keane, H. Shimasaki, O. S. Privett, 1978, Radiation research.

INCIDENCE AND TYPE OF INFECTIONS OCCURRING IN 445 CHRONIC HEMODIALYSIS PATIENTS

W. Keane, L. Raij, F. Shapiro, 1977, Transactions - American Society for Artificial Internal Organs.

The pharmacokinetics of losartan in renal insufficiency

W. Keane, S. Shahinfar, C. Halstenson, 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Disposition of Famotidine in Renal Insufficiency

W. Keane, G. Matzke, C. Halstenson, 1987, Journal of clinical pharmacology.

Age is a determinant of the glomerular morphologic and functional responses to chronic nephron loss.

B. Kasiske, W. Keane, L. Raij, 1985, The Journal of laboratory and clinical medicine.

Isoprenoids and Ras: potential role in chronic rejection.

B. Kasiske, Z. Massy, W. Keane, 1995, Kidney international. Supplement.

Cefsulodin pharmacokinetics during hemodialysis.

W. Keane, G. Matzke, 1982, Transactions - American Society for Artificial Internal Organs.

Pharmacokinetics of vancomycin in patients with various degrees of renal function

W. Keane, G. Matzke, C. Halstenson, 1984, Antimicrobial Agents and Chemotherapy.

Nephropathy in diabetes.

Mark E Molitch, H. Parving, R. DeFronzo, 2004, Diabetes care.

Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs.

W. Keane, P. Abraham, 1984, American journal of nephrology.

Assessment of structure and function in progressive renal disease.

G. Eknoyan, W. Mitch, G. Striker, 1997, Kidney international. Supplement.

The renin-angiotensin system in the type II diabetic obese Zucker rat.

B. Kasiske, W. Keane, S. Katz, 1993, Journal of the American Society of Nephrology : JASN.

The long-term tolerability of enalapril in hypertensive patients with renal impairment.

W. Keane, S. Shahinfar, E. Faison, 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Human peritoneal macrophage cytotoxicity mediated by cytophilic IgG.

W. Keane, H. Verbrugh, P. Peterson, 1983, The Journal of infectious diseases.

Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.

D. de Zeeuw, S. Anderson, W. Keane, 1989, Annals of internal medicine.

Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice.

H. Rabb, F. Daniels, W. Keane, 2000, American journal of physiology. Renal physiology.

Effects of cyclosporine on the isolated perfused rat kidney.

B. Kasiske, W. Keane, G. Matzke, 1987, Transplantation.

Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells.

W. Keane, P. Peterson, G. Gekker, 1987, The Journal of clinical investigation.

Cholesterol-Lowering Effects oHypercholesterolemiain Patients With Mild to Moderate Hypercholesterolemia

W. Keane, C. Halstenson, L. Bell, 1992 .

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Zhongxin Zhang, Giuseppe Remuzzi, B. Brenner, 2004, Kidney international.

Antifungal, Antitubercular, and Antiviral Agents

W. Keane, G. Matzke, M. H. Schwenk, 1988 .

Cefsulodin pharmacokinetics in patients with various degrees of renal function

W. Keane, G. Matzke, 1983, Antimicrobial Agents and Chemotherapy.

Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation.

B. Kasiske, H. Parving, P. Bennett, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients.

W. Keane, R. Nelson, H. Suh, 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency

W. Keane, G. Matzke, C. Halstenson, 1991, Antimicrobial Agents and Chemotherapy.

Antihypertensive Therapy with Once‐daily Administration of Terazosin, a New Alpha1‐adrenergic‐receptor Blocker

W. Keane, G. Matzke, C. Halstenson, 1985, Pharmacotherapy.

Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.

W. Keane, G. Matzke, C. Halstenson, 1985, American journal of nephrology.

Pharmacologic Treatment of Hyperlipidemia Reduces Glomerular Injury in Rat 5/6 Nephrectomy Model of Chronic Renal Failure

B. Kasiske, W. Keane, W. Garvis, 1988, Circulation research.

Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis.

W. Keane, C. Peterson, M. Bullock, 1981, The New England journal of medicine.

Association between active Wegener's granulomatosis and anticytoplasmic antibodies.

C. Kallenberg, A. Fauci, J. Velosa, 1989, Archives of internal medicine.

The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury.

B. Kasiske, W. Keane, W F Keane, 1992, Hypertension.

Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis

B. Kasiske, W. Keane, Jennie Z. Ma, 1993, Annals of Internal Medicine.

Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure.

W. Keane, C. Dinarello, A. Ney, 1991, Journal of the American Society of Nephrology : JASN.

Prevention of diabetic renal disease with special reference to microalbuminuria

H. Parving, P. Bennett, G. Jerums, 1995, The Lancet.

Reviews and Original Articles

B. Piraino, T. Golper, F. Schaefer, 1996 .

Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure.

W. Keane, H. Rabb, N. Yokota, 2001, Kidney international.

Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages

W. Keane, H. Suh, P. Peterson, 1985, Infection and immunity.

A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18.

G. Fantuzzi, W. Keane, C. Dinarello, 2001, Cytokine.

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies

B. Brenner, H. Parving, G. Remuzzi, 2007, Journal of hypertension.

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

B. Brenner, J. McGill, R. Toto, 2003, Kidney international.

Proteinuria: its clinical importance and role in progressive renal disease.

W. Keane, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The role of lipids in renal disease: future challenges.

W. Keane, William F. Keane, 2000, Kidney international. Supplement.

Renal injury of diet-induced hypercholesterolemia in rats.

B. Kasiske, W. Keane, P. Schmitz, 1990, Kidney international.

Glomerular hemodynamic and structural alterations in experimental diabetes mellitus

B. Kasiske, W. Keane, M. O'Donnell, 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation.

G. Eknoyan, W. Keane, W F Keane, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

B. Brenner, W. Gerth, E. Dasbach, 2003, Diabetes care.

Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP).

M. Klag, W. Keane, W. Brown, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis.

W. Keane, A. J. Collins, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages.

W. Keane, H. Suh, P. Peterson, 1985, Endocrinology.

Pharmacokinetics of Tazobactam M1 Metabolite After Administration of Piperacillin/Tazobactam in Subjects with Renal Impairment

W. Keane, C. Lathia, K. Tantillo, 1994, Journal of clinical pharmacology.

Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program.

W. Keane, W. Brown, D. Molony, 2003, Kidney international. Supplement.

Irreversible acute renal failure in idiopathic nephrotic syndrome.

W. Keane, L. Raij, A. Leonard, 1976, The American journal of medicine.

Effects of carbohydrate restriction on renal injury in the obese Zucker rat.

B. Kasiske, W. Keane, M. Cleary, 1986, The American journal of clinical nutrition.

Host Defense Mechanisms of the Peritoneal Cavity and Continuous Ambulatory Peritoneal Dialysis

W. Keane, P. Peterson, 1991 .

Mild hypothermia gives better functional preservation than cold or normothermic perfusion of rat kidneys.

B. Kasiske, W. Keane, K. Berens, 1990, Transplantation proceedings.

Angiotensin-Converting Enzyme Inhibitors in Chronic Renal Failure

W. Keane, J. Opsahl, P. Abraham, 2012, Drugs.

Renal effects of angiotensin converting enzyme inhibitors: Nondiabetic chronic renal disease

W. Keane, J. Opsahl, P. Abraham, 2005, Cardiovascular Drugs and Therapy.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Zhongxin Zhang, Giuseppe Remuzzi, Janet B McGill, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Recent advances in statins and the kidney.

H. Oda, W. Keane, William F. Keane, 1999, Kidney international. Supplement.

Immunosuppressive effects of leflunomide in experimental chronic vascular rejection.

B. Kasiske, W. Keane, S. Swan, 1995, Transplantation.

Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity.

W. Keane, P. Peterson, G. Gekker, 1987, Journal of immunology.

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.

Zhongxin Zhang, B. Brenner, R. Toto, 2004, Kidney international.

Proteinuria and cardiovascular disease.

W. Keane, W. Weinstock Brown, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Role of hypertension in progressive glomerular immune injury.

W. Keane, L. Raij, S. Azar, 1985, Hypertension.

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

W. Keane, P. Lyle, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Losartan: lessons learned from the RENAAL study

B. Brenner, W. Keane, S. Shahinfar, 2006, Expert opinion on pharmacotherapy.

Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure.

B. Kasiske, F. Daniels, W. Keane, 2001, Kidney international.

Metabolic pathogenesis of cardiorenal disease.

W. Keane, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Hyperlipidemia and progressive renal disease.

B. Kasiske, W. Keane, Y. Kim, 1991, Kidney international. Supplement.

Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program.

G. Bakris, R. Grimm, W. Keane, 2005, Kidney international.

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

M. Schluchter, B. Brenner, J. McGill, 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Diabetes in the elderly population.

W. Keane, M. Khan, A. J. Collins, 2000, Advances in renal replacement therapy.

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study

J. Chan, M. Cooper, W. Keane, 2006, Clinical and Experimental Nephrology.

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

B. Brenner, W. Gerth, E. Dasbach, 2012, PharmacoEconomics.

Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis.

B. Kasiske, Z. Massy, H. Oda, 1999, Kidney international. Supplement.

The national epidemic of chronic kidney disease

G. Eknoyan, A. Levey, W. Keane, 2001, Postgraduate medicine.

Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease

W. Keane, C. Halstenson, M. Affrime, 1992 .

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

B. Brenner, D. de Zeeuw, S. Snapinn, 2005, Journal of the American Society of Nephrology : JASN.

The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference

P. Whelton, E. Schiffrin, G. Bakris, 2000, Journal of clinical pharmacology.

Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.

B. Kasiske, H. Oda, W. Keane, 1997, Kidney international. Supplement.

Cefotaxime and desacetyl cefotaxime kinetics in renal impairment

W. Keane, G. Matzke, C. Halstenson, 1985, Clinical pharmacology and therapeutics.

Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians.

B. Kasiske, W. Keane, S. Rith-Najarian, 1996, Clinical nephrology.

Kidney disease and cardiovascular disease: implications of dyslipidemia.

W. Keane, P. Lyle, 2005, Cardiology clinics.

Intestinal and Hepatic Cholesterol Synthesis in the Alloxan Diabetic Rat 1

W. Keane, M. Goodman, L. Michels, 1982, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Treatment of Peritonitis: Update or New Course

W. Keane, S. Vas, 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

A Large Step in the Treatment of Peritonitis in Peritoneal Dialysis Patients

W. Keane, S. Vas, 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain.

W. Keane, G. Matzke, C. Halstenson, 1988, American journal of nephrology.

High protein intake accelerates glomerulosclerosis independent of effects on glomerular hemodynamics.

B. Kasiske, F. Daniels, W. Keane, 1990, Kidney international.

Diabetic nephropathy.

H. Parving, R. DeFronzo, W. Keane, 2003, Diabetes care.

Antibiotics: Antianaerobic Agents, Quinolones, and Tetracyclines

W. Keane, M. H. Schwenk, Gary R. Matzke, 1988 .